Pasithea Therapeutics Corp. (NASDAQ:KTTA) Sees Large Decline in Short Interest

Pasithea Therapeutics Corp. (NASDAQ:KTTAGet Free Report) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 9,300 shares, a decline of 31.1% from the January 15th total of 13,500 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 93,100 shares, the days-to-cover ratio is currently 0.1 days.

Pasithea Therapeutics Stock Performance

Shares of KTTA stock opened at $5.92 on Tuesday. The stock’s fifty day moving average price is $7.09 and its 200 day moving average price is $8.56. Pasithea Therapeutics has a 1-year low of $5.25 and a 1-year high of $17.40.

Pasithea Therapeutics (NASDAQ:KTTAGet Free Report) last issued its quarterly earnings results on Monday, November 13th. The company reported ($2.80) EPS for the quarter.

Institutional Trading of Pasithea Therapeutics

An institutional investor recently raised its position in Pasithea Therapeutics stock. Vanguard Group Inc. boosted its position in shares of Pasithea Therapeutics Corp. (NASDAQ:KTTAFree Report) by 345.5% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 56,583 shares of the company’s stock after acquiring an additional 43,883 shares during the quarter. Vanguard Group Inc. owned about 0.25% of Pasithea Therapeutics worth $74,000 at the end of the most recent reporting period. 7.48% of the stock is owned by hedge funds and other institutional investors.

Pasithea Therapeutics Company Profile

(Get Free Report)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers.

Featured Articles

Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with's FREE daily email newsletter.